Abstract
Cancer cell heterogeneity is a universal feature of human tumors and represents a significant barrier to the efficacy and duration of anticancer therapies, especially targeted therapeutics. Among the heterogeneous cancer cell populations is a subpopulation of relatively quiescent cancer cells, which are in the G0/G1 cell-cycle phase and refractory to anti-mitotic drugs that target proliferative cells. These slow-cycling cells (SCCs) preexist in untreated tumors and frequently become enriched in treatment-failed tumors, raising the possibility that these cells may mediate therapy resistance and tumor relapse. Here we review several general concepts on tumor cell heterogeneity, quiescence, and tumor dormancy. We discuss the potential relationship between SCCs and cancer stem cells (CSCs). We also present our current understanding of how SCCs and cancer dormancy might be regulated. Increasing knowledge of SCCs and tumor dormancy should lead to identification of novel molecular regulators and therapeutic targets of tumor relapse, residual diseases, and metastasis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Liu, X., et al. (2015). Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells. Oncotarget, 6(27), 23959–23986.
Moore, N., & Lyle, S. (2011). Quiescent, slow-cycling stem cell populations in cancer: A review of the evidence and discussion of significance. Journal of Oncology, 2011, 396076.
Tang, D. G. (2012). Understanding cancer stem cell heterogeneity and plasticity. Cell Research, 22(3), 457–472.
Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews. Cancer, 7(11), 834–846.
Salm, S., Burger, P. E., & Wilson, E. L. (2012). TGF-beta and stem cell factor regulate cell proliferation in the proximal stem cell niche. Prostate, 72(9), 998–1005.
Salm, S. N., et al. (2005). TGF-beta maintains dormancy of prostatic stem cells in the proximal region of ducts. The Journal of Cell Biology, 170(1), 81–90.
Santoni-Rugiu, E., et al. (2005). Progenitor cells in liver regeneration: Molecular responses controlling their activation and expansion. APMIS, 113(11–12), 876–902.
Mishra, L., et al. (2005). The role of TGF-β and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene, 24(37), 5775–5789.
Wilson, A., & Trumpp, A. (2006). Bone-marrow haematopoietic-stem-cell niches. Nature Reviews. Immunology, 6(2), 93–106.
Yadav, A. S., et al. (2018). The biology and therapeutic implications of tumor dormancy and reactivation. Frontiers in Oncology, 8, 72.
Sun, Q., et al. (2012). Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice. BMC Medicine, 10, 172.
Almog, N. (2010). Molecular mechanisms underlying tumor dormancy. Cancer Letters, 294(2), 139–146.
Sosa, M. S., Bragado, P., & Aguirre-Ghiso, J. A. (2014). Mechanisms of disseminated cancer cell dormancy: An awakening field. Nature Reviews. Cancer, 14(9), 611–622.
Jeter, C. R., et al. (2009). Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells, 27(5), 993–1005.
Qin, J., et al. (2012). The PSA(−/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell, 10(5), 556–569.
Tang, D. G., et al. (2007). Prostate cancer stem/progenitor cells: Identification, characterization, and implications. Molecular Carcinogenesis, 46(1), 1–14.
Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3(7), 730–737.
Collins, A. T., et al. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research, 65(23), 10946–10951.
Singh, S. K., et al. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Research, 63(18), 5821–5828.
Wright, M. H., et al. (2008). Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Research, 10(1), R10.
Roesch, A., et al. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell, 141(4), 583–594.
Roesch, A., et al. (2013). Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell, 23(6), 811–825.
Kester, L., & van Oudenaarden, A. (2018). Single-cell transcriptomics meets lineage tracing. Cell Stem Cell, 23(2), 166–179.
Zhao, T., et al. (2018). Single-cell RNA-Seq reveals dynamic early embryonic-like programs during chemical reprogramming. Cell Stem Cell, 23(1), 31–45.e7.
Li, L., & Clevers, H. (2010). Coexistence of quiescent and active adult stem cells in mammals. Science, 327(5965), 542–545.
Zhang, D., et al. (2018). Histone 2B-GFP label-retaining prostate luminal cells possess progenitor cell properties and are intrinsically resistant to castration. Stem Cell Reports, 10(1), 228–242.
Sakaue-Sawano, A., et al. (2008). Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell, 132(3), 487–498.
Zielke, N., & Edgar, B. A. (2015). FUCCI sensors: Powerful new tools for analysis of cell proliferation. Wiley Interdisciplinary Reviews: Developmental Biology, 4(5), 469–487.
Drost, J., & Clevers, H. (2018). Organoids in cancer research. Nature Reviews. Cancer, 18(7), 407–418.
Miller, M. A., & Weissleder, R. (2017). Imaging of anticancer drug action in single cells. Nature Reviews. Cancer, 17(7), 399–414.
van der Toom, E. E., Verdone, J. E., & Pienta, K. J. (2016). Disseminated tumor cells and dormancy in prostate cancer metastasis. Current Opinion in Biotechnology, 40, 9–15.
Chen, X., et al. (2016). Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate Cancer. Clinical Cancer Research, 22(17), 4505–4516.
Horning, A. M., et al. (2018). Single-cell RNA-seq reveals a subpopulation of prostate cancer cells with enhanced cell-cycle-related transcription and attenuated androgen response. Cancer Research, 78(4), 853–864.
Perego, M., et al. (2018). A slow-cycling subpopulation of melanoma cells with highly invasive properties. Oncogene, 37(3), 302–312.
Tsujimura, A., et al. (2002). Proximal location of mouse prostate epithelial stem cells: A model of prostatic homeostasis. The Journal of Cell Biology, 157(7), 1257–1265.
Lawson, D. A., et al. (2007). Isolation and functional characterization of murine prostate stem cells. Proceedings of the National Academy of Sciences of the United States of America, 104(1), 181–186.
Burger, P. E., et al. (2005). Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proceedings of the National Academy of Sciences of the United States of America, 102(20), 7180–7185.
Lawson, D. A., et al. (2010). Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proceedings of the National Academy of Sciences of the United States of America, 107(6), 2610–2615.
Xin, L., Lawson, D. A., & Witte, O. N. (2005). The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 102(19), 6942–6947.
Xin, L., et al. (2007). Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells, 25(11), 2760–2769.
Wang, Z. A., et al. (2013). Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nature Cell Biology, 15(3), 274–283.
Choi, N., et al. (2012). Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell, 21(2), 253–265.
Wang, X., et al. (2009). A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature, 461(7263), 495–500.
Karthaus, W. R., et al. (2014). Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell, 159(1), 163–175.
Ousset, M., et al. (2012). Multipotent and unipotent progenitors contribute to prostate postnatal development. Nature Cell Biology, 14(11), 1131–1138.
Zhang, D., et al. (2017). Developing a novel two-dimensional culture system to enrich human prostate luminal progenitors that can function as a cell of origin for prostate Cancer. Stem Cells Translational Medicine, 6(3), 748–760.
Zhang, D., et al. (2016). Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer. Nature Communications, 7, 10798.
Bhatia, B., et al. (2008). Critical and distinct roles of p16 and telomerase in regulating the proliferative life span of normal human prostate epithelial progenitor cells. The Journal of Biological Chemistry, 283(41), 27957–27972.
Rycaj, K., et al. (2016). Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells. Oncotarget, 7(12), 14220–14240.
Patrawala, L., et al. (2006). Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene, 25(12), 1696–1708.
Patrawala, L., et al. (2005). Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Research, 65(14), 6207–6219.
Patrawala, L., et al. (2007). Hierarchical organization of prostate cancer cells in xenograft tumors: The CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Research, 67(14), 6796–6805.
Patrawala, L. T., & G, D. (2007). CD44 as a functional cancer stem cell marker and a potential therapeutic target. In Autologous and cancer stem cell gene therapy (pp. 317–334). Singapore: World Scientific Publishing.
Choi, E., et al. (2018). Lrig1+ gastric isthmal progenitor cells restore normal gastric lineage cells during damage recovery in adult mouse stomach. Gut, 67(9), 1595–1605.
Jensen, K. B., et al. (2009). Lrig1 expression defines a distinct multipotent stem cell population in mammalian epidermis. Cell Stem Cell, 4(5), 427–439.
Jensen, K. B., & Watt, F. M. (2006). Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence. Proceedings of the National Academy of Sciences of the United States of America, 103(32), 11958–11963.
Powell, A. E., et al. (2012). The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell, 149(1), 146–158.
Wang, Y., Poulin, E. J., & Coffey, R. J. (2013). LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. British Journal of Cancer, 108(9), 1765–1770.
Wong, V. W., et al. (2012). Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nature Cell Biology, 14(4), 401–408.
Linde, N., Fluegen, G., & Aguirre-Ghiso, J. A. (2016). The relationship between dormant cancer cells and their microenvironment. Advances in Cancer Research, 132, 45–71.
Acknowledgments
Work in the authors’ lab was supported by grants from the U.S. National Institutes of Health (NIH) (R01CA237027 and R21CA218635), Department of Defense (W81XWH-16-1-0575), and RPCCC and NCI grant P30CA016056.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Davis, J.E., Kirk, J., Ji, Y., Tang, D.G. (2019). Tumor Dormancy and Slow-Cycling Cancer Cells. In: Rhim, J., Dritschilo, A., Kremer, R. (eds) Human Cell Transformation. Advances in Experimental Medicine and Biology, vol 1164. Springer, Cham. https://doi.org/10.1007/978-3-030-22254-3_15
Download citation
DOI: https://doi.org/10.1007/978-3-030-22254-3_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-22253-6
Online ISBN: 978-3-030-22254-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)